445 completed, 170 recruiting, 165 unknown, 138 terminated. 1129 Phase 3, 122 Phase 2.
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2027-03-02 | 2026-10-28 |
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | AbbVie | 660 | 2027-01-06 | 2026-10-05 |
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | PrECOG, LLC. | 430 | 2027-01-01 | 2026-06-09 |
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) Plinabulin, Docetaxel, Placebo (matching plinabulin placebo) - Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance | Phase 3 | Not yet recruiting | BeyondSpring Pharmaceuticals Inc. | 442 | 2026-12-01 | 2026-09-29 |
| A Phase 3 Trial in Advanced Epithelioid Mesothelioma VT3989, gemcitabine, Vinorelbine - Pleural Mesothelioma, Mesothelioma | Phase 3 | Not yet recruiting | Vivace Therapeutics, Inc | 350 | 2026-12-01 | 2026-09-17 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 950 | 2026-11-01 | 2026-10-28 |
| A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer HS-10370, Adebrelimab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 448 | 2026-10-31 | 2026-09-16 |
| A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC Adebrelimab (SHR-1316) + chemotherapy, Adebrelimab - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Not yet recruiting | West China Hospital | 1088 | 2026-10-31 | 2026-10-26 |
| A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer JYP0322 Tablets, Crizotinib Capsules - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Not yet recruiting | Guangzhou JOYO Pharma Co., Ltd | 216 | 2026-10-30 | 2026-09-22 |
| Primary Radiotherapy In MEtastatic Lung Cancer Radiotherapy followed by chemotherapy, Standard of Care (SOC) - Carcinoma, Non-Small-Cell Lung (NSCLC) | Phase 3 | Recruiting | Trans Tasman Radiation Oncology Group | 420 | 2026-10-30 | 2026-10-23 |
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 556 | 2026-10-15 | 2026-09-03 |
| A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) Divarasib, Pembrolizumab, Nivolumab - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 400 | 2026-10-06 | 2026-10-13 |
| Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Recruiting | Multitude Therapeutics Inc. | 512 | 2026-09-30 | 2026-10-26 |
| Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose - Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Swiss Cancer Institute | 230 | 2026-09-29 | 2026-10-28 |
| A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants ABBV-1480, Pembrolizumab, Carboplatin - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 940 | 2026-09-22 | 2026-10-20 |
| Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin) - Advanced or Metastatic NSCLC | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 206 | 2026-09-17 | 2026-08-10 |
Showing 20 of 1129. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (813) · Lung Neoplasms (360) · Small Cell Lung Carcinoma (129) · Neoplasms (54) · Adenocarcinoma of Lung (43) · Neoplasm Metastasis (40) · Brain Neoplasms (28) · Breast Neoplasms (23) · Parkinson Disease 4, Autosomal Dominant Lewy Body (23) · Carcinoma (19) · Prostatic Neoplasms (17) · Mesothelioma, Malignant (16) · Adenocarcinoma, Bronchiolo-Alveolar (14) · Lung Diseases (14)
Neoplasms by Site (1121) · Respiratory Tract Neoplasms (1111) · Respiratory Tract Diseases (1104) · Lung Diseases (1088) · Neoplasms (1075) · Bronchial Neoplasms (922) · Carcinoma, Bronchogenic (922) · Lung Neoplasms (752) · Neoplasms by Histologic Type (116) · Neoplasms, Glandular and Epithelial (104) · Pathological Conditions, Signs and Symptoms (93) · Carcinoma (69) · Pathologic Processes (62) · Adenocarcinoma (52)
Carboplatin (274) · Cisplatin (229) · Pemetrexed (194) · Paclitaxel (149) · Docetaxel (133) · pembrolizumab (116) · Gemcitabine (88) · Etoposide (68) · Radiotherapy (57) · Erlotinib Hydrochloride (52) · Vinorelbine (44) · Gefitinib (43) · durvalumab (43) · Bevacizumab (41) · atezolizumab (40)
AstraZeneca (45) · Merck Sharp & Dohme LLC (44) · Hoffmann-La Roche (40) · Eli Lilly and Company (27) · Bristol-Myers Squibb (26) · National Cancer Institute (NCI) (26) · Alliance for Clinical Trials in Oncology (24) · Pfizer (19) · Boehringer Ingelheim (16) · Novartis Pharmaceuticals (14) · Sun Yat-sen University (14) · AbbVie (12) · Amgen (12) · GlaxoSmithKline (12) · European Organisation for Research and Treatment of Cancer - EORTC (10)
United States (463) · China (449) · Italy (298) · Spain (291) · France (285) · Germany (274) · Canada (269) · South Korea (257) · United Kingdom (251) · Poland (248) · Australia (214) · Taiwan (214) · Japan (202) · Belgium (198) · Brazil (198)
PMID 37419867, PMID 25881079, PMID 37465924, PMID 38642841, PMID 40311309, PMID 28472437, PMID 28501139, PMID 33337539, PMID 34870327, PMID 36184621, PMID 38468440, PMID 39113428, PMID 41332393, PMID 15764775, PMID 21714641, PMID 22266043, PMID 22547591, PMID 23948351, PMID 25589191, PMID 26051236, PMID 26768165, PMID 26823294, PMID 26906526, PMID 27130468, PMID 27138015, PMID 27458945, PMID 27601237, PMID 29290251, PMID 29653820, PMID 31395089, PMID 32305010, PMID 33075149, PMID 33231285, PMID 33300372, PMID 33358660, PMID 34409776, PMID 35073727, PMID 35511917, PMID 35930972, PMID 36793385, PMID 36795388, PMID 37704166, PMID 37922432, PMID 38159809, PMID 38383458, PMID 39230120, PMID 39369790, PMID 39661917, PMID 39992021, PMID 40421698
2023 (53), 2025 (18), 2017 (16), 2018 (16), 2014 (15), 2015 (15), 2019 (14), 2016 (10), U10CA031946 (9), 2009 (8), U10CA180820 (8), U10CA180888 (8), U10CA180868 (7), U10CA180821 (6), 2005 (4)